Large-scale TIDES purification with MCSGP under GMP

Throughout industry the trend goes from producing batches to continuous production. Due to the increasing need for efficient methods to produce peptides and oligonucleotides on a large scale, Bachem was the first TIDES manufacturer to introduce Multicolumn Countercurrent Solvent Gradient Purification (MCSGP) systems for their continuous purification. Now being able to purify faster and very sustainably tens of kilograms of TIDES under GMP conditions, the company’s leading technologist in this field explains along with two of the fathers of this technology, Prof. Morbidelli and Thomas Müller-Späth, what makes MCSGP the new industry standard.

 

About the Speakers

Ralf Eisenhuth Ph.D.

Principal Process Manager Chromatography

With a Ph.D. in organic chemistry from the University of Karlsruhe, Ralf Eisenhuth joined Bachem AG in 2008. Over the last decade, he held several positions at Bachem: ranging from process development to leading the large-scale purification of peptides at the Bubendorf site. In his current position as Process Manager of Chromatography and Technology Transfer, he is focusing on innovative purification technologies and processes. He is an inventor on several patents. 

Keith Porter

Business Development Manager

Keith Porter studied Organic  Chemistry and Materials Science at the University of Illinois Urbana Champaign. Keith has more than ten years of research and development experience in the field of solid-phase peptide synthesis (SPPS) and spent most of his career striving to improve this technique. In 2021, he joined Bachem as Business Development Manager. Keith published several scientific articles during his career. 

Prof. Massimo Morbidelli

Cofounder ChromaCon AG

Massimo Morbidelli received his Laurea in Chemical Engineering at the Polytechnic University of Milan and PhD at the University of Notre Dame. Currently, he is Professor Emeritus at the ETH Zurich and at the Polytechnic University of Milan and a member of the Italian Academy of Sciences (Accademia dei Lincei). Furthermore, he is the recipient of the ERC Advanced Grant on Continuous Digitalized Bioprocesses (CoDiBio). His main research interests are biopharmaceutics, the integrated continuous manufacturing of therapeutic proteins, and its automation and digitalization. He is co-author of more than 750 papers, 23 international patents, and 6 books. He is a cofounder of ChromaCon Ltd., a spin-off company from his research group, now acquired by YMC, Japan.

Thomas Müller-Späth, Ph.D.

CEO and Cofounder of ChromaCon AG

Thomas Müller-Späth, Dr. sc. ETH, Dipl.-Ing., is CEO and co-founder of ChromaCon AG, a YMC company. Thomas studied Chemical Engineering at the Technical University of Hamburg, and at the University of California, Berkeley. In 2008, he obtained his Ph.D. for investigating multi‑column technology for the purification of proteins at the Swiss Federal Institute of Technology (ETH Zurich) in the group of Prof. Morbidelli. He is an inventor on several patents, and author of numerous scientific articles on continuous chromatography for biopharmaceuticals.

Webinars